Will Integra LifeSciences (IART) beat quarterly earnings? Odds & Prediction Markets

Name: Will Integra LifeSciences (IART) beat quarterly earnings?
Start: 2026-10-07T19:20:14.000Z
End: 2026-10-21T13:00:00.000Z

Description

This group asks whether Integra LifeSciences (IART) will exceed the consensus estimate for non-GAAP earnings per share (EPS) in its next quarterly report. The current consensus estimate is $0.57. Resolution will primarily rely on the company's official earnings documents, with fallback mechanisms to SeekingAlpha and then GAAP EPS if non-GAAP EPS is unavailable.

PredictionHero - Resolution Divergence Alerts (RDA)

Unified Resolution Criteria (Consistent across platforms)

Both platforms utilize identical resolution criteria and source prioritization, ensuring consistent market behavior.Primary resolution logic: Integra LifeSciences official earnings documents

Core resolution logic:

Resolution is based on non-GAAP EPS exceeding $0.57.
If non-GAAP EPS is unavailable, resolution falls back to SeekingAlpha's non-GAAP EPS.
If SeekingAlpha's non-GAAP EPS is unavailable, resolution falls back to official GAAP EPS.
If official GAAP EPS is unavailable, resolution falls back to SeekingAlpha's GAAP EPS.
If all EPS data is unavailable, the market resolves to 'No'.

Edge cases & clarifications:

Earnings Delay: If Integra LifeSciences does not release earnings within 45 calendar days of the estimated date (October 21, 2026), the market will resolve to 'No'.
Restatements: Subsequent restatements are generally ignored, except for obvious and immediate errors (e.g., 'fat finger' mistakes).
Multiple EPS Figures: The primary headline non-GAAP EPS number will be used, typically diluted. If diluted is not published, basic non-GAAP EPS will be used.

Timing: Resolution will occur after Integra LifeSciences releases its quarterly earnings report and the relevant EPS figures are available, with a maximum of 96 hours after market close on the earnings announcement day to resolve based on SeekingAlpha data if necessary.Our PredictionHero Resolution Divergence Alerts (RDA) are there to help users identify potential differences across platforms. They do not replace or supersede the official rules and description of any prediction market. Users are solely responsible for reviewing and understanding the applicable rules and resolution criteria before placing any trade or bet. If you notice a potential inconsistency, discrepancy, or error in an alert, please report it to our team so we can review and improve the accuracy of our data.

Polymarket

As of market creation, Integra LifeSciences is estimated to release earnings on October 21, 2026. The Street consensus estimate for Integra LifeSciences’s non-GAAP EPS for the relevant quarter is $0.57 as of market creation. This market will resolve to "Yes" if Integra LifeSciences reports non-GAAP EPS greater than $0.57 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents. If Integra LifeSciences releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.) If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets reflect the selected street consensus estimate for non-GAAP EPS as of market creation. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.

Limitless

As of market creation, Integra LifeSciences is estimated to release earnings on October 21, 2026. The Street consensus estimate for Integra LifeSciences’s non-GAAP EPS for the relevant quarter is $0.57 as of market creation. This market will resolve to "Yes" if Integra LifeSciences reports non-GAAP EPS greater than $0.57 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents. If Integra LifeSciences releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.) If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets reflect the selected street consensus estimate for non-GAAP EPS as of market creation. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.

Frequently asked questions

On Polymarket and Limitless, this dashboard tracks the consensus view on whether Integra LifeSciences (IART) will beat quarterly earnings expectations. Currently, the IART earnings market shows a combined volume of $578 and a 24-hour volume of $261. This allows traders to see how predictions are evolving across both platforms and provides a comprehensive overview of market sentiment. The dashboard aggregates data from both venues to give a holistic view of the probability assigned to this outcome, reflecting the collective wisdom of the crowd.

Prediction market odds often offer a distinct perspective compared to traditional analyst forecasts. While analysts rely on financial models and company reports, this market incorporates a wider range of information and real-time sentiment. The collective intelligence of traders can sometimes anticipate earnings surprises more accurately than individual analysts. Currently, the implied probability from this market is influenced by factors not always fully captured in standard financial analysis. Comparing the price action here to consensus analyst estimates can reveal discrepancies and potentially identify undervalued or overvalued expectations surrounding IART's performance.

Prices on Polymarket and Limitless may differ due to variations in trader demographics, liquidity, and platform-specific rules. Polymarket and Limitless can show different implied probabilities for the same outcome because of liquidity, fee structure, participant mix, and how each venue defines the contract. For example, Polymarket might attract more sophisticated traders with access to specialized information, while Limitless could have a broader base of participants with differing risk tolerances. These factors can lead to discrepancies in how quickly information is incorporated into the price. Additionally, differing trading fees or market-making incentives on each platform can contribute to price divergence. The spread between the two platforms reflects these underlying differences in market dynamics.

This market is scheduled to resolve around Oct 21, 2026. The outcome will be determined by whether Integra LifeSciences (IART) reports quarterly earnings that exceed analyst expectations, as verified against credible public reporting. The resolution will be based on official earnings releases and financial data publicly available following the earnings announcement. Traders will be able to view the confirmed outcome and settlement details on both Polymarket and Limitless once the event is finalized.

Several signals or events could significantly move this market before Oct 21, 2026. Any news regarding IART’s performance, such as pre-earnings announcements, changes in analyst ratings, or broader economic indicators impacting the healthcare sector, could influence trader sentiment. Unexpected developments within Integra LifeSciences, like a major product recall or a significant acquisition, would also likely cause price fluctuations. Macroeconomic factors, including interest rate changes or shifts in investor risk appetite, could indirectly affect the market. Monitoring these factors will be crucial for anyone looking to trade or analyze this market in the coming weeks.

Will Integra LifeSciences (IART) beat quarterly earnings?

Anthropic flags revenue surge to investors ahead of stock market debut

Asia Tech Selloff Shows China as Possible Bright Spot

Taiwan Dollar, Won Slump as Chip Stock Selloff Hurts Sentiment

Treasuries Extend Gains as Equities Selloff Dents Risk Sentiment

Gold Rises as Treasury Yields Erase Gain After Inflation Data

Bitcoin Slides as Wall Street Risk Pullback Tests Bullish Turn

Hot Inflation Print Pushes Wall Street to Raise Rate Hike Bets

The Former Theater Director Who Keeps Beating Wall Street

L&G Is Hedging Its Bond Purchases Against Risk of Selloff

Asian Stocks Bounce as Tech Rebounds From Selloff: Markets Wrap